HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Intermittent continuous iv infusion of high-dose cyclophosphamide for remission induction in acute lymphocytic leukemia.

Abstract
Cyclophosphamide was administered to 42 patients with acute lymphocytic leukemia (ALL) as a daily continuous iv infusion at a dose of 400 mg/m2/day x 5 days; the courses of treatment were repeated every 3 weeks. Of the 42 patients entered, 21 achieved a complete response, two achieved a partial response, 12 failed to respond, and seven were considered to have early deaths. The response rate was 69.5% if only patients who received adequate trials are considered; mean duration of response was 18.5 weeks and mean survival time was 24.2 weeks. Twenty-three patients had relapsed after previous chemotherapy, and 19 patients were untreated for advanced high-risk cases of ALL; no difference was found in the response rates, durations of response, and survival times between these groups. No significant genitourinary toxicity occurred. Myelosuppression became the dose-limiting toxic effect. Continuous infusion of cyclophosphamide is a clinically effective method of ALL treatment and may have a role in the initial combination regimens for this hematologic malignancy.
AuthorsA Solidoro, J Otero, C Vallejos, L Casanova, F Salas, T Pasco, L Quiroz, O Orlandini, J Marcial
JournalCancer treatment reports (Cancer Treat Rep) 1981 Mar-Apr Vol. 65 Issue 3-4 Pg. 213-8 ISSN: 0361-5960 [Print] UNITED STATES
PMID6940657 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Cyclophosphamide
Topics
  • Adolescent
  • Adult
  • Child
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Drug Administration Schedule
  • Female
  • Humans
  • Infusions, Parenteral
  • Leukemia, Lymphoid (drug therapy, pathology)
  • Leukopenia (etiology)
  • Male
  • Middle Aged
  • Myeloproliferative Disorders (etiology)
  • Prognosis
  • Recurrence
  • Thrombocytopenia (etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: